Cargando…
Profile of adalimumab and its potential in the treatment of uveitis
Uveitis refers to the presence of intraocular inflammation, and as a strict definition compromises the iris and ciliary body anteriorly and the choroid posteriorly (the uvea). Untreated, uveitis can lead to visual loss or blindness. The etiology of uveitis can include both infectious and noninfectio...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034916/ https://www.ncbi.nlm.nih.gov/pubmed/27698552 http://dx.doi.org/10.2147/DDDT.S94188 |
_version_ | 1782455348975632384 |
---|---|
author | Balevic, Stephen J Rabinovich, C Egla |
author_facet | Balevic, Stephen J Rabinovich, C Egla |
author_sort | Balevic, Stephen J |
collection | PubMed |
description | Uveitis refers to the presence of intraocular inflammation, and as a strict definition compromises the iris and ciliary body anteriorly and the choroid posteriorly (the uvea). Untreated, uveitis can lead to visual loss or blindness. The etiology of uveitis can include both infectious and noninfectious (usually immune-mediated) causes, the latter of which are often mediated predominantly by Th1 CD4(+) T-cells that secrete proinflammatory cytokines. Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine involved in the pathogenesis of uveitis, which at high concentrations can cause excess inflammation and tissue damage. Adalimumab is a recombinant human IgG1 monoclonal antibody specific for human TNF-α. Historically, corticosteroids and methotrexate were used to treat uveitis; however, newer biologic agents such as adalimumab have revolutionized therapy for noninfectious uveitis. Adalimumab has shown efficacy in treating refractory uveitis in multiple settings, including idiopathic disease, juvenile idiopathic arthritis, sarcoidosis, Behçets disease, and uveitis secondary to spondyloarthropathies, among several other noninfectious uveitis conditions. In this paper, we will review the profile of adalimumab, the role of TNF-α in uveitis, discuss safety data, and summarize key articles evaluating the efficacy of adalimumab in treating uveitis secondary to the most commonly associated autoimmune diseases. |
format | Online Article Text |
id | pubmed-5034916 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-50349162016-10-03 Profile of adalimumab and its potential in the treatment of uveitis Balevic, Stephen J Rabinovich, C Egla Drug Des Devel Ther Review Uveitis refers to the presence of intraocular inflammation, and as a strict definition compromises the iris and ciliary body anteriorly and the choroid posteriorly (the uvea). Untreated, uveitis can lead to visual loss or blindness. The etiology of uveitis can include both infectious and noninfectious (usually immune-mediated) causes, the latter of which are often mediated predominantly by Th1 CD4(+) T-cells that secrete proinflammatory cytokines. Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine involved in the pathogenesis of uveitis, which at high concentrations can cause excess inflammation and tissue damage. Adalimumab is a recombinant human IgG1 monoclonal antibody specific for human TNF-α. Historically, corticosteroids and methotrexate were used to treat uveitis; however, newer biologic agents such as adalimumab have revolutionized therapy for noninfectious uveitis. Adalimumab has shown efficacy in treating refractory uveitis in multiple settings, including idiopathic disease, juvenile idiopathic arthritis, sarcoidosis, Behçets disease, and uveitis secondary to spondyloarthropathies, among several other noninfectious uveitis conditions. In this paper, we will review the profile of adalimumab, the role of TNF-α in uveitis, discuss safety data, and summarize key articles evaluating the efficacy of adalimumab in treating uveitis secondary to the most commonly associated autoimmune diseases. Dove Medical Press 2016-09-19 /pmc/articles/PMC5034916/ /pubmed/27698552 http://dx.doi.org/10.2147/DDDT.S94188 Text en © 2016 Balevic and Rabinovich. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Balevic, Stephen J Rabinovich, C Egla Profile of adalimumab and its potential in the treatment of uveitis |
title | Profile of adalimumab and its potential in the treatment of uveitis |
title_full | Profile of adalimumab and its potential in the treatment of uveitis |
title_fullStr | Profile of adalimumab and its potential in the treatment of uveitis |
title_full_unstemmed | Profile of adalimumab and its potential in the treatment of uveitis |
title_short | Profile of adalimumab and its potential in the treatment of uveitis |
title_sort | profile of adalimumab and its potential in the treatment of uveitis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034916/ https://www.ncbi.nlm.nih.gov/pubmed/27698552 http://dx.doi.org/10.2147/DDDT.S94188 |
work_keys_str_mv | AT balevicstephenj profileofadalimumabanditspotentialinthetreatmentofuveitis AT rabinovichcegla profileofadalimumabanditspotentialinthetreatmentofuveitis |